First National Bank & Trust Co. of Newtown reduced its holdings in shares of Shire PLC (NASDAQ:SHPG) by 25.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,968 shares of the biopharmaceutical company’s stock after selling 995 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Shire were worth $460,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in SHPG. YorkBridge Wealth Partners LLC lifted its stake in shares of Shire by 81.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares in the last quarter. BB&T Investment Services Inc. lifted its stake in shares of Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 786 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Shire during the 3rd quarter valued at approximately $159,000. Stephens Inc. AR lifted its stake in shares of Shire by 22.2% during the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares in the last quarter. Finally, Aureus Asset Management LLC purchased a new stake in shares of Shire during the 2nd quarter valued at approximately $212,000. Institutional investors own 20.23% of the company’s stock.
A number of brokerages recently commented on SHPG. BidaskClub cut shares of Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Piper Jaffray Companies restated a “hold” rating and set a $160.00 price target on shares of Shire in a research note on Friday, October 27th. Royal Bank of Canada restated a “buy” rating on shares of Shire in a research note on Thursday, November 16th. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Finally, Liberum Capital reiterated a “hold” rating on shares of Shire in a research note on Wednesday, December 20th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. Shire has an average rating of “Hold” and an average price target of $212.18.
Shire PLC (NASDAQ SHPG) traded down $1.59 during midday trading on Wednesday, reaching $145.96. 2,141,800 shares of the company’s stock traded hands, compared to its average volume of 1,296,020. Shire PLC has a fifty-two week low of $137.17 and a fifty-two week high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The stock has a market cap of $44,550.00, a PE ratio of 27.49, a PEG ratio of 0.79 and a beta of 1.59.
Shire (NASDAQ:SHPG) last posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business had revenue of $3.70 billion for the quarter. During the same quarter in the prior year, the company earned $3.17 earnings per share. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. analysts forecast that Shire PLC will post 15 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/01/17/first-national-bank-trust-co-of-newtown-sells-995-shares-of-shire-plc-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.